Article

FDA approves olaparib for germline BRCA-mutated metastatic breast cancer

2018-01-12

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 80df0cee-0504-5114-b029-d752fd765cb3
DOI: 10.31525/fda1-ucm592357.htm

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

FDA approves olaparib for germline BRCA-mutated metastatic breast cancerDOI 10.31525/fda1-ucm592357.htmRead

Olaparib for Metastatic Germline BRCA-Mutated Breast CancerSemantic proximity Read

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationSemantic proximity Read

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)Semantic proximity Read

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)Semantic proximity Read

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerSemantic proximity Read

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerSemantic proximity Read

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast CancerSemantic proximity Read

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.Semantic proximity Read

First PARP Inhibitor Ok'd for Breast CancerSemantic proximity Read

Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiADSemantic proximity Read

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid BiopsySemantic proximity Read